Free tool
Drug Trial Radar: Gastroenterology and liver
Last checked: Nov 20, 2026Latest source record: Nov 21, 2022 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
56
Completed, industry sponsors, Gastroenterology and liver, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
56 trials
Showing 1 to 25, recently updated first.
- Efficacy and Safety Evaluation of Neobianacid® in GERD and EPSPivotal-lookingCompleted
Aboca Spa Societa' AgricolaIndustry
NCT03238534 · 275 participants · Start Sep 12, 2017 · Primary completion Sep 3, 2021
Drug: Omeprazole 20mg · For: GERD; EPS
Sites: Latina, Italy; L’Aquila, Italy; Pavia, Italy · 12 sites in all
- Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Reflux DiseasePivotal-lookingCompleted
HK inno.N CorporationIndustry
NCT05267743 · 218 participants · Start Feb 16, 2021 · Primary completion May 25, 2022
Drug: Tegoprazan 50mg QD; Lansoprazole 30mg QD · For: Erosive Reflux Disease
Sites: Iksan, South Korea
HK inno.N CorporationIndustry
NCT04309916 · 46 participants · Start May 22, 2020 · Primary completion Nov 30, 2021
Drug: Tegoprazan; Esomeprazole · For: Erosive Reflux Disease
Sites: Seoul, South Korea
Geophyt S.r.l.s.Industry
NCT02573844 · 30 participants · Start Jan 2015 · Primary completion Oct 2017
Drug: Proklama; Placebo · For: Irritable Bowel Syndrome
Sites: Pavia, Italy
AllerganAbbVie (ABBV)
NCT03441581 · 24 participants · Start Feb 23, 2018 · Primary completion Apr 28, 2020
Drug: Eluxadoline · For: Irritable Bowel Syndrome With Diarrhea
Sites: Rochester, Minnesota
Dong-A ST Co., Ltd.Industry
NCT03910361 · 51 participants · Start Apr 12, 2019 · Primary completion Jul 2, 2020
Drug: Evogliptin; Pioglitazone · For: Type2 Diabetes; Non-Alcoholic Fatty Liver Disease
Sites: Changwon, South Korea; Cheonan, South Korea; Daegu, South Korea · 7 sites in all
- Clinical Trial to Evaluate the Efficacy and Safety of EsoDuo Tab. 20/800mgPivotal-lookingCompleted
Chong Kun Dang PharmaceuticalIndustry
NCT03928470 · 379 participants · Start Jan 29, 2019 · Primary completion Dec 20, 2019
Drug: EsoDuo Tab. 20/800mg · For: Non-erosive Reflux Disease(NERD)
Sites: Busan, South Korea; Cheonan, South Korea; Cheongju-si, South Korea · 38 sites in all
- An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic ConstipationPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT02590432 · 828 participants · Start Nov 1, 2015 · Primary completion Feb 5, 2018
Drug: Linaclotide · For: Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation
Sites: Anniston, Alabama; Athens, Alabama; Childersburg, Alabama · 79 sites in all
Dr. Falk Pharma GmbHIndustry
NCT01510860 · 65 participants · Start Nov 2008 · Primary completion Jul 2010
Drug: UDCA (Ursodeoxycholic acid); UDCA (Ursodeoxycholic acid) · For: Primary Biliary Cirrhosis
Sites: Munich, Germany
- Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide UsePivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT02959983 · 346 participants · Start Oct 25, 2016 · Primary completion Jan 22, 2018
Drug: Eluxadoline; Placebo · For: Irritable Bowel Syndrome With Diarrhea
Sites: Huntsville, Alabama; Saraland, Alabama; Phoenix, Arizona · 83 sites in all
- The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux DiseasePivotal-lookingCompleted
Torax Medical IncorporatedIndustry
NCT02505945 · 152 participants · Start Jun 2015 · Primary completion Oct 2017
Drug: Omeprazole · For: GERD Gastroesophageal Reflux Disease
Sites: Mobile, Alabama; Heber Springs, Arkansas; Los Angeles, California · 21 sites in all
- Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated TabletsCompleted
Neutec Ar-Ge San ve Tic A.ŞIndustry
NCT03037606 · 48 participants · Start Aug 1, 2017 · Primary completion Dec 1, 2018
Drug: Rabelis DDR 50 mg Capsules; Pariet 20 mg Enteric Coated Tablets · For: Gastroesophageal Reflux Disease
Sites: Izmir, Turkey (Türkiye)
TakedaTakeda (TAK)
NCT02351960 · 296 participants · Start Mar 19, 2015 · Primary completion Jun 22, 2016
Drug: Dexlansoprazole · For: Gastroesophageal Reflux Disease
Sites: Shatin, Hong Kong; Gyeonggi-do, South Korea; Seoul, South Korea · 10 sites in all
Neutec Ar-Ge San ve Tic A.ŞIndustry
NCT02689999 · 12 participants · Start Feb 2016 · Primary completion May 2017
Drug: Dexrabeprazole 10 mg Enteric-Coated Tablets · For: Gastroesophageal Reflux Disease (GERD)
Sites: Izmir, Turkey (Türkiye); Ankara, Turkey (Türkiye); Samsun, Turkey (Türkiye)
- The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal AcidityCompleted
Neutec Ar-Ge San ve Tic A.ŞIndustry
NCT02958046 · 12 participants · Start Jan 2014 · Primary completion May 2015
Drug: Lansoprazole/Domperidone · For: Gastroesophageal Reflux Disease
Sites: Izmir, Turkey (Türkiye)
- Efficacy and Saafety of Omez Iin Patients With H.Pylori Associated DiseasesPivotal-lookingCompleted
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT02922699 · 120 participants · Start Jan 2013 · Primary completion Jun 2013
Drug: OMEZ 40; OMEZ 80 · For: GERD
Astellas Pharma IncAstellas (ALPMY)
NCT00918411 · 98 participants · Start Jun 2009 · Primary completion Dec 2009
Drug: Ramosetron; Placebo · For: Irritable Bowel Syndrome
Sites: Hokkaido, Japan; Kansai, Japan; Kantou, Japan · 4 sites in all
Chong Kun Dang PharmaceuticalIndustry
NCT01860482 · 39 participants · Start Apr 2013 · Primary completion May 2015
Drug: Newrabell® Tablet 10mg · For: Reflux Esophagitis
Sites: Gwangju, South Korea · 2 sites in all
GlaxoSmithKlineGSK (GSK)
NCT00370032 · 49 participants · Start Dec 2006 · Primary completion Dec 2007
Drug: alosetron · For: Irritable Colon
Sites: London, United Kingdom
- Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study USPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00660660 · 276 participants · Start Apr 2008 · Primary completion Jul 2008
Drug: Esomeprazole; Placebo · For: Gastroesophageal Reflux Disease
Sites: Huntsville, Alabama; Tucson, Arizona; Little Rock, Arkansas · 45 sites in all
- Comparative Efficacy and Safety of FenoverinePivotal-lookingCompleted
Bukwang PharmaceuticalIndustry
NCT01507922 · 186 participants (planned) · Start Dec 2011 · Primary completion Mar 2013
Drug: Fenoverine; Timebutine · For: Irritable Bowel Syndrome
Sites: Ansan, South Korea; Anyang, South Korea; Chuncheon, South Korea · 7 sites in all
- Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)Pivotal-lookingCompleted
Laboratoires Mayoly SpindlerIndustry
NCT01404923 · 436 participants · Start Dec 2009 · Primary completion Oct 2011
Drug: anti spasmodic agents; alverine citrate, simeticone · For: Irritable Bowel Syndrome
- A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male PatientsPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT01225237 · 296 participants · Start Oct 2010 · Primary completion Aug 2011
Drug: Ramosetron; Placebo · For: Irritable Bowel Syndrome
Sites: Hokkaido, Japan; Kansai, Japan; Kantou, Japan · 4 sites in all
Janssen-Cilag Pty LtdJohnson & Johnson (Janssen) (JNJ)
NCT00464308 · 1,392 participants · Start Nov 2006 · Primary completion May 2008
Drug: Esomeprazole; Rabeprazole and 1 more · For: Gastro-oesophageal Reflux
Sites: Belconnen, Australia; Bondi Junction, Australia; Brookvale, Australia · 25 sites in all
AstraZenecaAstraZeneca (AZN)
NCT01397084 · 107 participants · Start Aug 2011 · Primary completion Jan 2012
Drug: esomeprazole 20 mg · For: Gastroesophageal Reflux Disease; GERD; Reflux Esophagitis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.